| Search for content and authors |
|
|
| |
 |
dr Zofia Mazerska |
| e-mail: | |
| phone: | +48-58-3472407 |
| fax: | +48-58-3471516 |
| web: | |
| interest(s): | |
|
Affiliation: |
Department of Pharmaceutical Technology and Biochemistry, Gdansk University of Technology|
| address: | Narutowicza St 11/12, Gdańsk, 80-233, Poland | | phone: | | | fax: | | | web: | | |
Participant: |
|
Participant: |
|
Participant: |
|
Participant: |
|
Participant: |
|
Publications: |
- Glucuronidation of antitumor agents - detoxification, mechanism of drug resistance or the prodrug design? Studies on acridine antitumor agents in the light of clinical therapeutics
- Imidazoacridinone antitumor agent, C-1311, as a selective mechanism-based inactivator of human recombinant cytochrome P450 1A2.
- Metabolic transformations of antitumor agents with cytochrome P-450 isoenzymes
- METABOLIC TRANSFORMATIONS OF ANTITUMOR AGENTS WITH CYTOCHROME P-450 ISOENZYMES.
- Metabolism of antitumor 9-amino-1-nitroacridine derivative C-1748 (Capridine-beta) in human hepatoma HepG2 cells
- Polymorphism and the level of P450 gene expression in drug metabolism
- Specific metabolism of antitumor agents with cytochrome P-450 isoenzymes
- The role of Cytochrome P450 Reductase in metabolism of potent nitroacridine antitumor agent, C‑1748.
- The role of hepatic cytochrome P-450 enzymes in metabolism of imidazoacridinone antitumor agent, C1311 (SymadexR): studies with the hepatic NADPH:cytochrome P450 reductase null mice
|